Review Explores Evidence for Folic Acid Supplementation to Prevent Neural Tube Defects

Why It Matters

Standardizing folic‑acid dosing fills a critical gap in countries lacking mandatory food fortification, reducing preventable birth defects and associated healthcare costs.

Key Takeaways

• Global NTD rate 18.6 per 10,000 births.
• 75% of NTD infants die before age five.
• 0.4 mg daily for low‑risk women recommended.
• Start folic acid three months before conception.
• Routine folate testing not required.

Pulse Analysis

Neural tube defects remain a pressing global health challenge, affecting roughly 18.6 infants per 10,000 births and leading to a 75% mortality rate before age five. The burden is disproportionately high in low‑ and middle‑income countries where more than 40% of women of reproductive age experience folate insufficiency. Without mandatory folic‑acid fortification, many pregnancies lack the critical nutrient needed during the narrow window of neural‑tube closure, underscoring the urgency for effective supplementation strategies.

The review by Lee et al. consolidates evidence from 17 international studies to outline clear, evidence‑based guidelines. It advises women to begin a daily 0.4 mg folic‑acid regimen at least three months prior to conception, scaling up to 1 mg for moderate risk and 4–5 mg for high‑risk cases, and to maintain supplementation through the first trimester. Importantly, the authors caution against relying on multivitamins for high‑dose folic acid, which can inadvertently deliver excess vitamin A, a known teratogen. Routine serum folate testing is also discouraged, simplifying clinical workflows.

For policymakers and health educators, these findings provide a concrete framework to design targeted interventions, especially in regions without food fortification mandates. Integrating the dosage recommendations into prenatal care protocols and community outreach can bridge knowledge gaps, improve supplement adherence, and ultimately lower NTD incidence. As healthcare systems adopt these guidelines, they can anticipate reduced long‑term disability costs and a measurable improvement in maternal‑child health outcomes.